ASLN vs. AIMD, KA, PULM, TENX, HILS, ENVB, SHPH, IBIO, RNAZ, and PCSA
Should you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Ainos (AIMD), Kineta (KA), Pulmatrix (PULM), Tenax Therapeutics (TENX), Hillstream BioPharma (HILS), Enveric Biosciences (ENVB), Shuttle Pharmaceuticals (SHPH), iBio (IBIO), TransCode Therapeutics (RNAZ), and Processa Pharmaceuticals (PCSA). These companies are all part of the "pharmaceutical preparations" industry.
Ainos (NASDAQ:AIMD) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk.
In the previous week, ASLAN Pharmaceuticals had 3 more articles in the media than Ainos. MarketBeat recorded 4 mentions for ASLAN Pharmaceuticals and 1 mentions for Ainos. ASLAN Pharmaceuticals' average media sentiment score of 0.38 beat Ainos' score of 0.00 indicating that Ainos is being referred to more favorably in the media.
Ainos has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.
58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 4.6% of Ainos shares are owned by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ASLAN Pharmaceuticals has a consensus target price of $11.33, suggesting a potential upside of 2,715.73%. Given Ainos' higher possible upside, analysts plainly believe ASLAN Pharmaceuticals is more favorable than Ainos.
Ainos has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Ainos is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ASLAN Pharmaceuticals received 200 more outperform votes than Ainos when rated by MarketBeat users.
ASLAN Pharmaceuticals has a net margin of 0.00% compared to ASLAN Pharmaceuticals' net margin of -11,205.49%. ASLAN Pharmaceuticals' return on equity of -47.96% beat Ainos' return on equity.
Summary
ASLAN Pharmaceuticals beats Ainos on 10 of the 16 factors compared between the two stocks.
Get ASLAN Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ASLAN Pharmaceuticals Competitors List
Related Companies and Tools
